2021
Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2001
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
Montgomery E, Goldblum J, Greenson J, Haber M, Lamps L, Lauwers G, Lazenby A, Lewin D, Robert M, Washington K, Zahurak M, Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Human Pathology 2001, 32: 379-388. PMID: 11331954, DOI: 10.1053/hupa.2001.23511.Peer-Reviewed Original ResearchConceptsHigh-grade dysplasiaLow-grade dysplasiaBarrett's esophagusInvasive carcinomaMajority diagnosisCases of HGDCases of LGDCases of BEEndoscopic biopsy specimensKaplan-Meier statisticsInitial biopsyEndoscopic surveillanceUlcerated areaGastrointestinal pathologyBiopsy specimenPredictive markerBiopsy diagnosisBiopsy specimensIntramucosal carcinomaPrecursor lesionsIND casesPowerful prognosticatorCarcinomaMorphologic evaluationUlcerated cases